Khan, A.A. http://orcid.org/0000-0003-3733-8956
Josse, R.
Kannu, P.
Villeneuve, J.
Paul, T.
Van Uum, S.
Greenberg, C.R.
Funding for this research was provided by:
Canadian Endocrine Update, McMaster University and Western University (2018)
Article History
Received: 17 September 2018
Accepted: 27 February 2019
First Online: 26 March 2019
Change Date: 29 May 2019
Change Type: Correction
Change Details: In the article mentioned above an author’s name was misspelled.
Compliance with ethical standards
:
: AK, research funds from Shire, Alexion, and Amgen. RJ, grants/research support: Amgen, AZ, Lilly, speakers Bureau/Honoraria: Amgen, Lilly, Merck, NovoNordisk, advisory board member: Amgen, Merck, Janssen, AZ, Lilly/BI. PK, Alexion honorariums. JV, scientific comity: Amgen and Eli Lilly, Speaker: Amgen and Eli Lilly. TP, no disclosures. SVU, relationships with for-profit and not-for-profit interests; grants/research support: Novartis, Sanofi, speakers Bureau/Honoraria: Abbott, Acerus pharmaceuticals, Novartis, Ipsen, Sanofi, Consulting Fees: Pfizer, other: annual speaker for Addison society. CRG was the Canadian site investigator during the industry-sponsored asfotase alfa clinical trials for which she received grant support from Alexion Pharmaceuticals, Inc. as well as consultancy fees and honoraria for select presentations.